Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 46 Lung Neoplasms 19 Melanoma 18 Neoplasm Metastasis 16 Carcinoma, Hepatocellular 15 Neoplasms 13 Esophageal Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 10 Colorectal Neoplasms 9 Breast Neoplasms 9 Head and Neck Neoplasms 8 Stomach Neoplasms 6 Rectal Neoplasms 6 Esophageal Squamous Cell Carcinoma 6 Carcinoma, Renal Cell 6 Brain Neoplasms 6 Small Cell Lung Carcinoma 5 Recurrence 5 Pancreatic Neoplasms 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Sarcoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Multiple Myeloma 4 Liver Neoplasms 4 Glioblastoma 4 Cholangiocarcinoma 4 Prostatic Neoplasms 3 Nasopharyngeal Carcinoma 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle-Invasive Bladder Carcinoma × Immunotherapy × Clear all

NCT04724928 2025-01-15

EFFORT-MIBC

University Hospital, Ghent

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡